Metabolism and acid secretory effect of sulfated and nonsulfated gastrin-6 in humans

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 279, Issue 5 42-5, 2000, Pages

  Palnaes Hansen C ^a,b   Stadil, F ^a   Rehfeld, J F ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b Rigshospitalet   (Denmark)

Author keywords

Gastric acid; Pharmacodynamics; Pharmacokinetics

Indexed keywords

GASTRIN; GASTRIN 17; GASTRIN 6; PENTAGASTRIN; PEPTIDE DERIVATIVE; PROGASTRIN; TYROSINE SULFATE; UNCLASSIFIED DRUG;

ACID SECRETION; ADULT; CONFERENCE PAPER; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENCY; FEMALE; HALF LIFE TIME; HUMAN; HUMAN EXPERIMENT; MALE; METABOLIC CLEARANCE RATE; NORMAL HUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; STOMACH ACID; STOMACH SECRETION;

EID: 0033673041     PISSN: 01931857     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpgi.2000.279.5.g903     Document Type: Conference Paper

References (31)

1. Measurements and occurrence of sulfated gastrins
2. The clinical use of gastric function tests
3. Gastric acid and pepsin-stimulating activity of nonsulfated fragments of gastrin in the cat
4. Does sulfation of gastrin influence gastric acid secretion in man?
5. Cholecystokinetic and pancreazymic effects of O-sulfated gastrin compared with nonsulfated gastrin and cholecystokinin
6. Reappraisal of the secretory potency and disappearance rate of pure human minigastrin
7. A comparison of estimates of Michaelis-Menten kinetic constants from various linear transformations
8. Similar acid stimulatory potencies of synthetic human big and little gastrin in man
9. The antral hormone gastrin: Structure of gastrin
10. Isolation from porcine antral mucosa a hexapeptide corresponding to the C-terminal sequence of gastrin
11. The constitution and properties of two gastrins extracted from hog antral mucosa
12. Comparison of effect of peptide length and sulfation on acid secretory potency of gastrin in the cat in vivo and in vitro
13. Sensitivity of parietal cells to gastrin in the cat: Comparison with man and dog
14. Understanding the dose-effect relationship. Clinical application of pharmacokinetic-pharmacodynamic models
15. Protein sulfation on tyrosine
16. Degradation of cholecystokinin octapeptide, related fragments and analogs by human and rat plasma in vitro
17. Structure-function relationships in the active C-terminal tetrapeptide sequence of gastrin
18. Metabolism and influence of gastrin-52 on gastric acid secretion in humans
19. Comparison of the metabolism of sulfated and unsulfated heptadecapeptide gastrin in humans
20. Immunochemical studies on cholecystokinin. I. Development of sequence specific radioimmunoassays for porcine triacontapeptide cholecystokinin
21. Accurate measurement of cholecystokinin in plasma
22. Postpoly(Glu) cleavage and degradation modified by O-sulfated tyrosine: A novel posttranslational processing mechanism
23. Identification of gastrin component I as gastrin- 71. The largest possible bioactive progastrin product
24. The predominating molecular form of gastrin and cholecystokinin in the gut is a small peptide corresponding to their COOH-terminal tetrapeptide amide
25. Production and evaluation of antibodies for the radioimmunoassay of gastrin
26. Sulfonated enkephalin: An active peptide resistant to serum degradative proteolysis
27. 125I-labelled synthetic human gastrin I for radioimmunoanalysis
28. Determination of gastrin in serum. An evaluation of the reliability of a radioimmunoassay
29. Mucosal gastrin receptor. IV. Binding specificity
30. Role of gastrin as atrophic hormone
31. Clearance and acid-stimulating action of human big and little gastrins in duodenal ulcer subjects